SEC Form 4 · accession 0001225208-18-009580
Edwards Lifesciences Corp · EW
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Catherine M. Szyman
Officer — CVP, Critical Care & Vascular
Period of report
May 16, 2018
Accepted (ET)
May 18, 2018 · 8:20 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001099800
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 16, 2018 | M | 9,362 | $0.00 | A | 40,133 | D | |
| Common StockF1 | May 16, 2018 | F | 4,642 | $136.43 | D | 35,491 | D | |
| Common Stock | holding | — | — | — | 3,942 | I | By Spouse |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Performance RightsF1 | — | May 16, 2018 | M | 9,362 | D | — | May 31, 2018 | Common Stock | 9,362 | 0 | D |
Explanation of responses
- F1On May 14, 2015, the Reporting Person was granted a target number of shares (5,350) covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 16, 2018, the Compensation Committee of the Issuer's Board of Directors determined that 175% of the target shares vested as of May 14, 2018, and the actual number of shares vested are reflected on this Form. Such shares became issuable following the May 16, 2018 determination.
Remarks
This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.